United Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
United Therapeutics has a total shareholder equity of $5.7B and total debt of $500.0M, which brings its debt-to-equity ratio to 8.8%. Its total assets and total liabilities are $6.7B and $1.0B respectively. United Therapeutics's EBIT is $1.3B making its interest coverage ratio -9. It has cash and short-term investments of $3.0B.
Key information
8.8%
Debt to equity ratio
US$500.00m
Debt
| Interest coverage ratio | -9x |
| Cash | US$2.97b |
| Equity | US$5.70b |
| Total liabilities | US$1.03b |
| Total assets | US$6.72b |
Recent financial health updates
United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04
Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06Recent updates
Benign Growth For United Therapeutics Corporation (NASDAQ:UTHR) Underpins Its Share Price
Sep 27United Therapeutics: Economics Support Compounding Ability
Aug 20With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jul 26United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Jul 04United Therapeutics Corporation's (NASDAQ:UTHR) Business And Shares Still Trailing The Market
Jun 13United Therapeutics: Exciting Company With A Big Problem
Jun 02We Ran A Stock Scan For Earnings Growth And United Therapeutics (NASDAQ:UTHR) Passed With Ease
Apr 05United Therapeutics: Neutral Stance On Tyvaso's Patent Challenges And Future Growth Prospects
Mar 20Is United Therapeutics (NASDAQ:UTHR) A Risky Investment?
Mar 15Investors Aren't Entirely Convinced By United Therapeutics Corporation's (NASDAQ:UTHR) Earnings
Jan 02United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
Dec 08Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Nov 16United Therapeutics (NASDAQ:UTHR) Has A Rock Solid Balance Sheet
Sep 04Here's Why We Think United Therapeutics (NASDAQ:UTHR) Might Deserve Your Attention Today
Aug 07United Therapeutics (NASDAQ:UTHR) Seems To Use Debt Rather Sparingly
May 22Does United Therapeutics (NASDAQ:UTHR) Deserve A Spot On Your Watchlist?
Apr 25We Think United Therapeutics (NASDAQ:UTHR) Can Manage Its Debt With Ease
Feb 06With EPS Growth And More, United Therapeutics (NASDAQ:UTHR) Makes An Interesting Case
Jan 16Is United Therapeutics (NASDAQ:UTHR) Using Too Much Debt?
Oct 20United Therapeutics: Ability To Expand Tyvaso To Large IPF Market
Aug 24Do United Therapeutics' (NASDAQ:UTHR) Earnings Warrant Your Attention?
Aug 04United Therapeutics Q2 2022 Earnings Preview
Aug 02These 4 Measures Indicate That United Therapeutics (NASDAQ:UTHR) Is Using Debt Safely
Jul 17Financial Position Analysis
Short Term Liabilities: UTHR's short term assets ($3.6B) exceed its short term liabilities ($832.3M).
Long Term Liabilities: UTHR's short term assets ($3.6B) exceed its long term liabilities ($193.7M).
Debt to Equity History and Analysis
Debt Level: UTHR has more cash than its total debt.
Reducing Debt: UTHR's debt to equity ratio has reduced from 41% to 8.8% over the past 5 years.
Debt Coverage: UTHR's debt is well covered by operating cash flow (221.1%).
Interest Coverage: UTHR earns more interest than it pays, so coverage of interest payments is not a concern.